HRP20192043T1 - Pripravak za liječenje upalne bolesti zgloba - Google Patents
Pripravak za liječenje upalne bolesti zgloba Download PDFInfo
- Publication number
- HRP20192043T1 HRP20192043T1 HRP20192043TT HRP20192043T HRP20192043T1 HR P20192043 T1 HRP20192043 T1 HR P20192043T1 HR P20192043T T HRP20192043T T HR P20192043TT HR P20192043 T HRP20192043 T HR P20192043T HR P20192043 T1 HRP20192043 T1 HR P20192043T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- expression construct
- mannose
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Pripravak koji sadrži ekspresijski konstrukt bakterijskog plazmida IL-10, naznačen time što ekspresijski konstrukt IL-10 ekspresijski konstrukt sadrži bakterijsku okosnicu i sekvencu nukleinske kiseline koja kodira interleukin-10 za uporabu u postupku liječenja osteoartritisa ili reumatoidnog artritisa kod subjekta, te navedeni postupak uključuje ubrizgavanje pripravka u upaljeni zglob subjekta.
2. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u postupku ekspresijski konstrukt IL-10 daje sa adjuvantom.
3. Pripravak za uporabu prema patentnom zahtjevu 2, naznačen time što je adjuvant odabran između D-manoze, saharoze, glukoze, kalcijevog fosfata, dendrimera, oligonukleotida, hijaluronske kiseline visoke molekulske mase ili liposoma.
4. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sekvenca nukleinske kiseline koja kodira interleukin-10 ima aminokiselinsku supstituciju serina, alanina, treonina ili cisteina sa divljim tipom fenilalanina na položaju aminokiseline 129.
5. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sekvenca nukleinske kiseline koja kodira interleukin-10 kodira IL-10F129S.
6. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ekspresijski konstrukt sadrži najmanje jednu nuklearnu sekvencu koja cilja 5' na IL-10 kodirajuću sekvencu.
7. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ekspresijski konstrukt sadrži najmanje jednu nuklearnu sekvencu koja cilja 3' na IL-10 kodirajuću sekvencu.
8. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak sadrži mikročestice koje inkapsuliraju ekspresijski konstrukt.
9. Pripravak za uporabu prema patentnom zahtjevu 8, naznačen time što mikročestice sadrže polimer koji sadrži poli(mliječnu-ko-glikolnu kiselinu).
10. Pripravak za uporabu prema patentnom zahtjevu 9, naznačen time što mikročestice sadrže polimer koji sadrži 50:50 poli(mliječnu-ko-glikolnu kiselinu).
11. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što postupak uključuje primjenu pripravka koji sadrži 1-1000 µg bakterijskog ekspresijskog konstrukta IL-10 i 5-1000 µg D-manoze.
12. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u postupku D-manoza daje istovremeno s ekspresijskim konstruktom IL-10.
13. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u postupku D-manoza daje do deset dana prije primjene ekspresijskog konstrukta IL-10.
14. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što plazmidna DNA sadrži barem jednu nuklearnu sekvencu koja cilja oba 5' i 3' na IL-10 kodirajuću sekvencu.
15. Pripravak za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što zglob predstavlja koljeno, lakat, ručni zglob, gležanj, kuk, rame ili kralježnicu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361847851P | 2013-07-18 | 2013-07-18 | |
| EP18167083.7A EP3369435B1 (en) | 2013-07-18 | 2014-07-17 | Composition for the treatment of inflammatory joint disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192043T1 true HRP20192043T1 (hr) | 2020-02-07 |
Family
ID=52346725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181913TT HRP20181913T1 (hr) | 2013-07-18 | 2014-07-17 | Sastav za liječenje upale bolesti zglobova |
| HRP20192043TT HRP20192043T1 (hr) | 2013-07-18 | 2019-11-12 | Pripravak za liječenje upalne bolesti zgloba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181913TT HRP20181913T1 (hr) | 2013-07-18 | 2014-07-17 | Sastav za liječenje upale bolesti zglobova |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10512672B2 (hr) |
| EP (2) | EP3369435B1 (hr) |
| JP (4) | JP2016525522A (hr) |
| CY (2) | CY1120946T1 (hr) |
| DK (2) | DK3369435T3 (hr) |
| ES (2) | ES2700826T3 (hr) |
| HR (2) | HRP20181913T1 (hr) |
| HU (2) | HUE042463T2 (hr) |
| LT (2) | LT3021873T (hr) |
| PL (2) | PL3021873T3 (hr) |
| PT (2) | PT3021873T (hr) |
| RS (2) | RS59735B1 (hr) |
| SI (2) | SI3021873T1 (hr) |
| SM (2) | SMT201800655T1 (hr) |
| WO (1) | WO2015009955A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3021873T1 (sl) | 2013-07-18 | 2018-12-31 | Xalud Therapeutics, Inc. | Sestavek za zdravljenje vnetne sklepne bolezni |
| CN109477085B (zh) * | 2016-04-22 | 2023-08-01 | 萨鲁德医疗公司 | 增强白细胞介素10的抗炎作用的方法和组合物 |
| UY39298A (es) * | 2020-06-26 | 2022-01-31 | Amgen Inc | Muteínas de il-10 y proteínas de fusión de las mismas |
| US20250051412A1 (en) * | 2021-12-16 | 2025-02-13 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US6312680B1 (en) | 1990-06-29 | 2001-11-06 | Timothy R. Mosmann | Methods of treatment using cytokine synthesis inhibitory factor |
| EP0671933B1 (en) | 1992-08-20 | 1998-02-04 | Schering Corporation | Novel uses of il-10 |
| US5922018A (en) | 1992-12-21 | 1999-07-13 | Artann Corporation | Method for using a transrectal probe to mechanically image the prostate gland |
| US5373317B1 (en) | 1993-05-28 | 2000-11-21 | Welch Allyn Inc | Control and display section for borescope or endoscope |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| ES2328585T3 (es) | 1993-10-25 | 2009-11-16 | Canji, Inc. | Vector de adenovirus recombinante y metodo de utilizacion. |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| EP0769054B1 (en) | 1994-07-05 | 2000-07-26 | Steeno Research Group A/S | Immunomodulators |
| DE69534265T2 (de) | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| US5716804A (en) | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
| AU5689898A (en) | 1996-12-05 | 1998-06-29 | University Of Florida | Il-10 and tgf-beta for treating autoimmune disease |
| US6201880B1 (en) | 1996-12-31 | 2001-03-13 | Electro-Optical Sciences | Method and apparatus for electronically imaging a tooth through transillumination by light |
| US5783567A (en) | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
| US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU3063899A (en) | 1998-03-17 | 1999-10-11 | Schering Corporation | Use of il-10 to treat major depressive disorder |
| AU752658B2 (en) | 1998-05-06 | 2002-09-26 | Association Francaise Contre Les Myopathies | Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6165754A (en) | 1999-06-08 | 2000-12-26 | Cornell Research Foundation, Inc. | Method of expressing an exogenous nucleic acid |
| US20050129669A1 (en) | 1999-06-21 | 2005-06-16 | Transkaryotic Therapies, Inc., A Massachusetts Corporation | DNA construct for effecting homologous recombination and uses thereof |
| EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| AU2002217929A1 (en) | 2000-11-28 | 2002-06-11 | Sangamo Biosciences, Inc. | Modulation of gene expression using insulator binding proteins |
| JP2004515527A (ja) | 2000-12-13 | 2004-05-27 | メルクル・ゲーエムベーハー | 放出特性改良微粒子およびその製造方法 |
| AU2002311777A1 (en) * | 2001-04-17 | 2002-10-28 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
| US20030166593A1 (en) | 2001-04-30 | 2003-09-04 | Kenneth Chien | Non-viral vesicle vector for cardiac specific gene delivery |
| JP4578735B2 (ja) | 2001-08-28 | 2010-11-10 | オリンパス株式会社 | 内視鏡画像ファイリングシステム |
| JP2003146909A (ja) | 2001-11-07 | 2003-05-21 | Children's Hospital Of Philadelphia | 治療用ポリペプチドに対する免疫寛容の誘導 |
| CA2361462A1 (en) | 2001-11-07 | 2003-05-08 | Katherine A. High | Induction of tolerance to a therapeutic polypeptide |
| US6967018B2 (en) | 2002-01-11 | 2005-11-22 | Applied Genetic Technologies Corporation | Adiponectin gene therapy |
| AU2003221745A1 (en) | 2002-04-19 | 2003-11-03 | University Of Florida | rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES |
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| US20040186357A1 (en) | 2002-08-20 | 2004-09-23 | Welch Allyn, Inc. | Diagnostic instrument workstation |
| EP1572943B1 (en) | 2002-08-29 | 2015-04-22 | The Board of Trustees of The Leland S. Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
| US20040142893A1 (en) | 2002-10-21 | 2004-07-22 | Uichi Ikeda | Methods for treating and preventing vascular disease |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US7530946B2 (en) | 2003-08-15 | 2009-05-12 | Scimed Life Systems, Inc. | Compact endoscope |
| US7276486B2 (en) * | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
| BRPI0512814A (pt) | 2004-07-01 | 2008-04-08 | Univ Pittsburgh Of The Commmmo | exosomas imunossupressivas |
| US20060073119A1 (en) | 2004-09-01 | 2006-04-06 | Avigen, Inc. | Methods for treating neurodegenerative disorders |
| WO2006119170A2 (en) | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| DE602006011311D1 (de) | 2005-05-31 | 2010-02-04 | Univ Colorado | Il-10 mutante |
| EP2816118B1 (en) | 2005-05-31 | 2018-10-17 | The Regents of the University of Colorado, a body corporate | Methods for delivering genes |
| US20080274202A1 (en) | 2005-08-01 | 2008-11-06 | Kraig Richard P | Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents |
| US20100196492A1 (en) | 2007-03-08 | 2010-08-05 | Green Jordan J | Electrostatic coating of particles for drug delivery |
| US7846428B2 (en) * | 2007-10-05 | 2010-12-07 | Merial Limited | Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP2651407B1 (en) * | 2010-12-15 | 2016-12-21 | Olatec Industries LLC | 3-methanesulfonylpropionitrile for treating inflammation and pain |
| US20150044281A1 (en) | 2012-01-06 | 2015-02-12 | The Regents Of The University Of Colorado, A Body Corporate | Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| SI3021873T1 (sl) | 2013-07-18 | 2018-12-31 | Xalud Therapeutics, Inc. | Sestavek za zdravljenje vnetne sklepne bolezni |
| CN109477085B (zh) | 2016-04-22 | 2023-08-01 | 萨鲁德医疗公司 | 增强白细胞介素10的抗炎作用的方法和组合物 |
-
2014
- 2014-07-17 SI SI201430972T patent/SI3021873T1/sl unknown
- 2014-07-17 RS RS20191473A patent/RS59735B1/sr unknown
- 2014-07-17 SM SM20180655T patent/SMT201800655T1/it unknown
- 2014-07-17 JP JP2016527107A patent/JP2016525522A/ja not_active Withdrawn
- 2014-07-17 DK DK18167083T patent/DK3369435T3/da active
- 2014-07-17 HU HUE14826787A patent/HUE042463T2/hu unknown
- 2014-07-17 US US14/905,915 patent/US10512672B2/en active Active
- 2014-07-17 SM SM20190657T patent/SMT201900657T1/it unknown
- 2014-07-17 DK DK14826787.5T patent/DK3021873T3/en active
- 2014-07-17 PL PL14826787T patent/PL3021873T3/pl unknown
- 2014-07-17 HR HRP20181913TT patent/HRP20181913T1/hr unknown
- 2014-07-17 PT PT14826787T patent/PT3021873T/pt unknown
- 2014-07-17 ES ES14826787T patent/ES2700826T3/es active Active
- 2014-07-17 WO PCT/US2014/047071 patent/WO2015009955A1/en active Application Filing
- 2014-07-17 PT PT181670837T patent/PT3369435T/pt unknown
- 2014-07-17 LT LTEP14826787.5T patent/LT3021873T/lt unknown
- 2014-07-17 LT LTEP18167083.7T patent/LT3369435T/lt unknown
- 2014-07-17 EP EP18167083.7A patent/EP3369435B1/en active Active
- 2014-07-17 ES ES18167083T patent/ES2760902T3/es active Active
- 2014-07-17 HU HUE18167083A patent/HUE046944T2/hu unknown
- 2014-07-17 SI SI201431402T patent/SI3369435T1/sl unknown
- 2014-07-17 RS RS20181419A patent/RS57974B1/sr unknown
- 2014-07-17 EP EP14826787.5A patent/EP3021873B8/en active Active
- 2014-07-17 PL PL18167083T patent/PL3369435T3/pl unknown
-
2018
- 2018-11-28 CY CY181101297T patent/CY1120946T1/el unknown
-
2019
- 2019-10-31 US US16/670,987 patent/US20200093892A1/en not_active Abandoned
- 2019-11-01 JP JP2019199475A patent/JP7066669B2/ja active Active
- 2019-11-12 HR HRP20192043TT patent/HRP20192043T1/hr unknown
- 2019-12-03 CY CY20191101267T patent/CY1122673T1/el unknown
-
2021
- 2021-11-05 JP JP2021180762A patent/JP2022031682A/ja active Pending
-
2022
- 2022-06-21 US US17/845,101 patent/US20220313785A1/en not_active Abandoned
-
2023
- 2023-01-25 US US18/159,161 patent/US20230158114A1/en active Pending
-
2024
- 2024-11-29 JP JP2024207852A patent/JP2025023096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192043T1 (hr) | Pripravak za liječenje upalne bolesti zgloba | |
| HRP20191852T1 (hr) | Polipeptidi | |
| HRP20170482T1 (hr) | Sintetski peptidoglikani koji vežu hijaluronsku kiselinu, dobivanje, i postupci uporabe | |
| Gupta et al. | Polymeric hydrogels for controlled drug delivery to treat arthritis | |
| ME03582B (me) | Protutijela protiv tau i njihova upotreba | |
| BR112012016021A8 (pt) | Formulações estáveis para liofilização de partículas terapêuticas | |
| JP2010215657A5 (hr) | ||
| HRP20110320T1 (hr) | Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba | |
| Kwon et al. | Regulation of bone cell differentiation and activation by microbe-associated molecular patterns | |
| MX2010003574A (es) | Anticuerpos il-23. | |
| EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
| MX359954B (es) | Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado. | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| IN2014DN05670A (hr) | ||
| ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
| Wang et al. | Expanding from materials to biology inspired by biomineralization | |
| EA035991B9 (ru) | Новый полисахарид и его применения | |
| FI3712264T3 (fi) | Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon | |
| Ma et al. | Biomineralization: biomimetic synthesis of materials and biomimetic regulation of organisms | |
| EA201490032A1 (ru) | Лиофилизированные препараты fgf-18 | |
| JP2015524413A5 (hr) | ||
| IN2014DN06920A (hr) | ||
| JP2016525522A5 (hr) | ||
| EA201690659A1 (ru) | Композиции аморфного магнийзамещенного фосфата кальция и их применение |